HHLA2 and hepatocellular carcinoma: HHLA2 binds to its ligand TMGD2 (CD28H) in HCC to activate the JAT/STAT signaling pathway, leading to the dysfunction of T cells and promoting the immune tolerance of hepatoma cells [126].